tebentafusp + pembrolizumab

Tebentafusp is a first-in-class bispecific gp100 peptide-HLA-A*02:01-directed T cell receptor (TCR) CD3 T cell engager, developed as an immunotherapy for unresectable or metastatic uveal melanoma. It consists of a soluble TCR arm that binds to the Melanocyte protein PMEL (gp100) peptide presented by HLA-A*02:01 on tumor cells and an anti-CD3 single-chain variable fragment that engages and activates CD3+ T cells, leading to targeted lysis of melanoma cells. Pembrolizumab is a monoclonal antibody immune checkpoint inhibitor targeting the Programmed cell death protein 1 (PD1) receptor, used in various cancers including melanoma. The combination aims to enhance anti-tumor immune responses by both redirecting T cells toward tumor antigens (tebentafusp) and relieving inhibitory signaling on activated T cells (pembrolizumab). Tebentafusp was developed by Immunocore and is approved for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma[1][3][6]. Pembrolizumab was developed by Merck & Co. and is approved for multiple cancer indications[2].

Other names

tebentafusp-tebn